Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
LAWRENCEVILLE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) — Imunon, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, November 14, 2022 to discuss financial results for the third quarter ended September 30, 2022 and provide an update on its clinical development of GEN-1, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase II clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCINE, a proprietary, multivalent DNA-based plasmid technology utilizing synthetic, non-viral delivery vectors, being evaluated in proof-of-concept studies for superiority over current mRNA vaccines.
Related news for (IMNN)
- IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
- 24/7 Market News Snapshot 22 September, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)
- IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
- 24/7 Market News Snapshot 30 July, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/17/25 10:00 AM